orthospinenews.com /1 week ago

OrthoTrophix Presents Data on TPX-100, Meniscal Pathology and Structural Progression in Knee Osteoarthritis

FOSTER CITY, Calif., Nov. 9, 2026 /PRNewswire/ — OrthoTrophix, Inc., a privately held biopharmaceutical company, today announced data from two…

Read source
qchron.com /1 week ago

PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FD...

PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor respo...

Read source
newswire.com /6 days ago

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Re...

Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmarkTen of 47 patients receiving mipletamig combination therapy ad...

Read source
healio.com /1 week ago

ANGPTL4 inhibition appears to reduce triglycerides

CHICAGO — A monoclonal antibody that inhibits angiopoietin-like protein 4 was linked to triglyceride reduction at 12 weeks in adults with high triglycerides, researchers reported a...

Read source
newswire.com /1 month ago

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Figh...

Read source
pharmexec.com /3 weeks ago

<![CDATA[Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Frag...

Read source
biopharmadive.com /1 month ago

TRex Bio prices $117M IPO to support immune drug work

Eli Lilly is the largest equity holder in TRex, which is developing drugs that treat immunological conditions by activating “Treg” cells.

Read source
fightaging.org /1 week ago

Anti-Fibrotic Drug Rentosertib Reduces Proteomic Clock Age in Humans

Rentosertib is a TNIK inhibitor developed by In Silico Medicine in the course of the company's efforts to find drugs that can affect aging, shown to be anti-fibrotic, and thus rece...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.